German clinicians report the results of a multicentre observational study evaluating adults with SMA receiving nusinersen treatment:
- 78 patients, including 51 non-ambulatory patients, participated in the study,
- the measurement of motor action potential (CMAP) in two nerves of the upper limbs (ulnar and median) was chosen as the primary endpoint,
- measurements were taken every 4 months for 4.5 years,
- on average, MEPs did not change over this period despite treatment with nusinersen.
The authors believe that, unlike in children with SMA, where it is useful, the measurement of MEPs is of very limited value in adults receiving nusinersen.
